Ctsi awards translational research project grants – jacobs school of medicine and biomedical sciences – university at buffalo 7 data recovery keygen

• Co-investigators: Stephanie Anzman-Frasca, PhD, assistant professor of pediatrics; and Gale R. Burstein, MD, MPH, clinical professor of pediatrics; Dolores Funke; Julia Ravenscroft, PhD, School of Public Health and Health Professions; Jacqueline A. Vernarelli, PhD; and Janet Z. Yang, PhD, College of Arts and Sciences

Lead poisoning continues to be an important public health problem and requires effective solutions. Children with elevated blood lead concentrations (BLLs) are more likely to be from non-white families, low socioeconomic status backgrounds and urban centers.

These same communities are also more likely to consume nutritionally inadequate diets and develop nutrient deficiencies, some of the most important risk factors for elevated BLLs. There is widespread perception that diet can be used to manage elevated BLL in young children, based on recommendations from the Centers for Disease Control and Prevention (CDC).

But the evidence base behind these recommendations is incomplete, uncertain or simply unavailable. Furthermore, diet can be a source of exposure to other toxic chemicals, such as pesticides. Any dietary recommendations should take into account potential unintended consequences.

• to determine the extent to which diets consumed by children with lower vs. higher BLLs are associated with exposure to other toxic chemicals and important health outcomes, and contrast the diets of children from low-income households who have lower vs. higher BLLs

• Co-investigators: Peter L. Elkin, MD, professor and chair of biomedical informatics; Manoj J. Mammen, MD, assistant professor of medicine; Ekaterina I. Noyes, PhD, School of Public Health and Health Professions and research professor of surgery; Gregory Wilding, PhD, School of Public Health and Health Professions

• to identify temporal trends and practice patterns for inpatient, outpatient, emergency department health utilization and mortality among Medicaid patients by using existing de-identified demographic and claims data extracted from the New York State Medicaid Data Warehouse and NYS Cancer Registry data from years 2009-2016

• to determine if health care utilization patterns meet evidence-based care guidelines for diagnosis and timely treatment based on specification of surgery of the primary site and receipt of radiation or chemotherapy within the specified time for a given measure

The goal of the study will be to compare health utilization of low-income lung cancer cases with evidence-based guidelines for lung cancer and lay the groundwork for improving access to care and long-term health outcomes for rural and urban cancer survivors.

The study will take advantage of existing data resources to better understand lung cancer in WNY, and it will generate substantial data to inform models of care for rural and urban communities aimed at tackling the inequities of care and increased burden of disease faced by Medicaid-insured individuals with a diagnosis of cancer.

• Co-principal investigators: Elizabeth Griffiths, MD, clinical associate professor of medicine in the Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Roswell Park Comprehensive Cancer Center; and Michael Nemeth, PhD, Department of Medicine, Roswell Park Comprehensive Cancer Center

Myelodysplastic syndrome (MDS) is a slow-growing leukemia (AML) that is associated with aging. Most patients come to medical attention because they have low blood counts and the diagnosis is made after a doctor performs a bone marrow biopsy and evaluation of the blood.

The two approved drugs in this class are called decitabine and azacitidine, and they are believed to work by tricking cancer cells into turning back on important signals that the cancer cell has been ignoring or has turned off in order to grow faster.

Among the genes that get turned back on by the action of decitabine is NY-ESO-1. Some cancers turn this gene on, and when they do, the immune system can see it and can attack these cancer cells. Immune recognition of this gene in cancer is associated with slower cancer growth.

The researchers showed that MDS and AML patients getting decitabine turn on NY-ESO-1 in their cancer cells. They also showed that when cancer cells turn this gene on, educated immune cells that are trained to see NY-ESO-1 can kill these cancer cells.

The researchers have decided to add a new drug, called nivolumab, to their vaccine/decitabine combination. They hope that by combining these strategies, they will be able to effectively educate the immune system of patients with MDS to see and kill their own cancer cells.

• Co-investigators: Jill Halterman, MD; Stacie Lampkin, PharmD, clinical assistant professor of pediatrics; Heather K. Lehman, MD, clinical associate professor of pediatrics and chief of allergy/immunology and rheumatology; Healther Orom, PhD; and Gregory Wilding, PhD; both of School of Public Health and Health Professions

The researchers propose that a multifaceted intervention — that uses the Chronic Care Model as a framework to integrate the delivery of health services to children with asthma and from vulnerable populations — will reduce asthma morbidity and health inequities.

Aligning with Schools To Help Manage Asthma (Project ASTHMA) will be delivered in the community at school-based health centers that are established health care systems and therefore can improve the sustainability and reproducibility of this intervention.

The chronic care model provides guidance for creating a comprehensive system change that integrates several interventions and is more likely to be successful than individual interventions. The researchers hypothesize that this multifaceted, health services intervention will decrease the frequency of asthma symptoms, asthma exacerbations, missed school days and improve lung function and quality of life.

• Co-investigators: Lee D. Chaves, PhD, research assistant professor of medicine; Elie R. Chemaly, MD, PhD, clinical assistant professor of medicine; Robert J. Genco, PhD, DDS, School of Dental Medicine; Richard J. Quigg, MD, Arthur M. Morris Professor of medicine and chief of nephrology; and Umesh Sharma, MD, PhD, assistant professor of medicine

Their gut bacterial composition is altered by the uremic milieu and by multiple dietary and therapeutic interventions. Altered gut bacterial composition then worsens the underlying metabolic imbalances and inflammation, leading to increased atherosclerosis and CVD risk.

Moreover, using National Health and Nutrition Examination Survey participants’ data, the researchers have shown that yogurt consumption (as a natural source of probiotics) is associated with decreased odds of developing proteinuric kidney disease, suggesting a benefit of restoring microbial symbiosis in CKD patients to inhibit disease progression and the risk of CVD.

The researchers will evaluate the mechanisms by which P. Copri abundance is altered in peritoneal dialysis patients, examine its effects on local inflammatory cell populations and mechanistically decipher how P. Copri affects cholesterol homeostasis.

Fewer than 10 percent of people diagnosed with pancreatic cancer live beyond five years. Most patients with pancreatic cancer are diagnosed in late stages when potentially curative surgery is no longer an option. Efforts to be able to detect pancreatic cancers in earlier stages are crucial to help decrease the number of people who die from pancreatic cancer.

It has long been known that genetic information specific to cancer cells can be detected in the blood of some cancer patients. Current technologies are enabling the identification of this cancer-specific genetic information directly from blood samples allowing for “liquid biopsies” that offer the potential of making cancer diagnoses directly from blood tests.

The development of new liquid biopsy technologies that can identify smaller amounts of genetic information more economically could potentially lead to blood tests that are able to detect smaller, more curable tumors and could be used for lung cancer screening.

The recent identification of CRISPR-Cas systems, bacterial immune systems adapted to recognize specific genetic sequences, that can accurately detect very small quantities of specific genetic sequences are an attractive platform to develop next generation liquid biopsy tests that are not only accurate, but also economical.